- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- October 2024
- 195 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- April 2025
- 162 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 132 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 130 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 128 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 140 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 185 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Drug Pipelines
- March 2025
- 180 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Clinical Trials
- March 2025
- 60 Pages
Global
From €1138EUR$1,250USD£975GBP
- Drug Pipelines
- July 2024
- 80 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- June 2024
- 185 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- May 2024
- 185 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- February 2025
- 183 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- April 2018
- 470 Pages
Global
From €2730EUR$3,000USD£2,341GBP

Nivolumab is a type of immunotherapy drug used to treat skin cancer. It is a monoclonal antibody that works by blocking the activity of a protein called PD-1, which helps cancer cells evade the body's immune system. Nivolumab is used to treat advanced melanoma, a type of skin cancer, and is approved for use in combination with other drugs. It is also being studied for use in other types of skin cancer, such as squamous cell carcinoma and basal cell carcinoma.
Nivolumab is a relatively new drug, and is part of a growing class of immunotherapy drugs that are being used to treat cancer. It has been shown to be effective in treating advanced melanoma, and is being studied for use in other types of skin cancer.
Some companies in the Nivolumab market include Bristol-Myers Squibb, Merck, and Roche. Show Less Read more